An investor in NASDAQ:NLNK shares filed a lawsuit against NewLink Genetics over alleged violations of Federal Securities Laws.
Investors who purchased shares of NewLink Genetics Corp (NASDAQ:NLNK) have certain options and for certain investors are short and strict deadlines running. Deadline: July 11, 2016. NASDAQ:NLNK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The plaintiff claims that between September 17, 2013 and May 9, 2016 the Defendants made false and/or misleading statements and/or failed to disclose thatthe Company’s algenpantucel-L treatment was ineffective and potentially harmful to patients, and that as a result of the foregoing, NewLink’s public statements were materially false and misleading at all relevant times.
On February 29, 2016, NewLink Genetics Corpprovided an operational update and reported its fourth quarter and year end 2015 financial results. NewLink Genetics Corp reported that its annual Total Revenue declined from $172.59 million in 2014 to $68.50 million in 2015 and that its Net Income of $96.02 million in 2014 declined to a Net Loss of $40.38 million in 2015.
On April 29, 2016, NewLink Genetics Corp reported its first quarter 2016 financial results. NewLink Genetics Corp announced that its first quarer Total Revenue declined from $39.20 million for the first quarter 2014 to $5.71 million for the first quarter 2015 and that its Net Income of $11.19 million for the first quarter in 2014 turned into a Net Loss of $23.72 million for the first quarter 2015.
On May 09, 2016, NewLink Genetics Corp (NASDAQ:NLNK) announced the results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer. NewLink Genetics Corp said that the IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint. Shares of NewLink Genetics Corp (NASDAQ:NLNK) declined from $54.24 per share in September 2015 to as low as $9.23 per share on May 12, 2016.
On May 31, 0216, NASDAQ:NLNK shares closed at $11.73 per share.
Those who purchased NASDAQ:NLNK shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com